GLP-1 and dual incretin agonists in obesity: 2025 state-of-the-art review
study113
10.1016/S2213-8587(25)00091-2
The Lancet Diabetes and Endocrinology
review article
State-of-the-art review on GLP-1 and dual/triple incretin agonists in obesity treatment.
Semaglutide, tirzepatide, and next-generation agents were described as reshaping obesity care.
semaglutide|tirzepatide|retatrutide
fat-loss|metabolism
metabolic-stack|advanced-metabolic-stack
semaglutide-vs-tirzepatide|retatrutide-vs-tirzepatide
published